Indaptus Therapeutics board member Tim Ruan resigns effective immediately
Indaptus disclosed in an SEC filing that director Tim Ruan stepped down from its board on September 2, 2026, with no stated dispute behind the move.
Indaptus Therapeutics, Inc. reported in a Form 8-K filed with the Securities and Exchange Commission that Tim Ruan notified the company's Board of Directors on September 2, 2026 of his resignation from the Board, effective immediately.1
The filing stated that the resignation did not stem from any disagreement with the company over its operations, policies, or practices.1
The report was signed on September 4, 2026 by Junyi Dai, identified as Chief Executive Officer of Indaptus Therapeutics. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the ticker symbol INDP. The filing did not disclose any replacement director or further details about the departure.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.